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Abstract: Voltage-gated calcium (CaV) channels are widely expressed and are essential for the
completion of multiple physiological processes. Close regulation of their activity by specific inhibitors
and agonists become fundamental to understand their role in cellular homeostasis as well as in human
tissues and organs. CaV channels are divided into two groups depending on the membrane potential
required to activate them: High-voltage activated (HVA, CaV1.1–1.4; CaV2.1–2.3) and Low-voltage
activated (LVA, CaV3.1–3.3). HVA channels are highly expressed in brain (neurons), heart, and
adrenal medulla (chromaffin cells), among others, and are also classified into subtypes which can be
distinguished using pharmacological approaches. Cone snails are marine gastropods that capture
their prey by injecting venom, “conopeptides”, which cause paralysis in a few seconds. A subset
of conopeptides called conotoxins are relatively small polypeptides, rich in disulfide bonds, that
target ion channels, transporters and receptors localized at the neuromuscular system of the animal
target. In this review, we describe the structure and properties of conotoxins that selectively block
HVA calcium channels. We compare their potency on several HVA channel subtypes, emphasizing
neuronal calcium channels. Lastly, we analyze recent advances in the therapeutic use of conotoxins
for medical treatments.
Keywords: conotoxins; voltage-gated calcium (CaV) channels; ω-conotoxin structure;
therapeutic potential
1. Introduction
Venomous cone snails (Conus) produce several toxic peptides, conopeptides, which target the
neuromuscular system of their prey, worms, mollusks, snails and fishes [1,2]. Conotoxins are peptides
of 20–30 residues whose main structural characteristic is a rigid backbone formed by disulfide bonds
between six cysteines. Conotoxins can be classified according to several criteria, including: a. the gene
superfamily they belong to; b. the pattern of cysteine distribution, cysteine framework; and c. their
molecular targets. Table 1 summarizes the known groups of conotoxins and their protein targets.
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Table 1. Classification of conotoxins and their molecular targets 1.
Conotoxin Family Molecular Target Reference
α (alpha) Nicotinic acetylcholine receptors (nAChR) [3]
γ (gamma) Neuronal pacemaker cation currents(inward cation current) [4]
δ (delta) Voltage-gated sodium (Na+) channels [5]
ε (epsilon) Presynaptic calcium (Ca
2+) channels or G
protein-coupled presynaptic receptors
[6]
ι (iota) Voltage-gated sodium (Na+) channels [7]
κ (kappa) Voltage-gated potassium (K+) channels [8]
µ (mu) Voltage-gated sodium (Na+)channels [9]
$ (rho) Alpha1-adrenoceptors (GPCR) [10]
σ (sigma) Serotonin-gated ion channels 5-HT3 [11]
τ (tau) Somatostatin receptor [12]
χ (chi) Neuronal noradrenaline transporter [10]
ω (omega) Voltage-gated calcium (CaV) channels [13]
1 Taken and adapted from www.conoserver.org [14,15].
The toxins produced by the genus Conus are numerous and diverse, and approximately
6200 different toxins have been isolated and identified from more than 100 different species thus
far [14,15]. The target of most of these toxins are ion channels, including voltage- and ligand-gated
channels, as well as G-protein coupled receptors [16,17]. In this review, we will focus onω-conotoxins,
which modulate CaV2.X channels. ω-conotoxins prevent entry of calcium (Ca2+) through these
voltage-activated CaV, channels at the presynaptic nerve terminal, thereby, interfering with the release
of vesicles containing acetylcholine and neurotransmission [13]. In general,ω-conotoxins impede Ca2+
flux by physically occluding the channel pore [18]. The kinetics of the binding is variable and can show
slow dissociation rates, generating poorly reversible blockage and long term inhibition [18].
1.1. Voltage-Gated Calcium Channels
Voltage-gated Ca2+ (CaV) channels are transmembrane proteins that belong to the same
transmembrane gene superfamily as the NaV and the KV channels. CaV channels can be organized
into two groups according to the voltage changes required for activation: Ca2+ channels that require
“larger” depolarizations to be opened (when compared with the current-voltage relation for INa) are
known as high-voltage activated (HVA) channels, whereas Ca2+ channels that open at more negative
potentials are known as low-voltage activated (LVA) [19]. CaVs are composed of a pore forming
subunit, α1, encoded by the CACNA1x genes (see Table 2). L-Type CaVs, CaV1.1–1.4, are known as α1S,
α1C, α1D, and α1F. The P/Q-, N- and R-type, CaV2.1–CaV2.3, are termed as α1A, α1B, and α1E. Finally,
the T-Type, CaV3, are composed of α1G, α1H, and α1I (Table 2 [20,21]). Depolarizations provoked
by the opening of CaV channels shape the action potential in the heart, regulate muscle contraction,
and modulate neurotransmitter secretion at nerve terminals. In general, “excitable cells translate their
electricity into action by Ca2+ fluxes modulated by voltage-sensitive, Ca2+-permeable channels” [19]. Once Ca2+
ions gain access to the cytosol, they act as second messengers, capable of binding thousands of proteins
affecting their localization and function. Variations of intracellular Ca2+ concentrations influence many
cell functions such as transcription, motility, apoptosis and initiation of development [22].
Table 2. Types of calcium channels in vertebrates [19,21].
Ca Channel Human Gene Name Voltage Activation α1 Subunit Ca Current
CaV1.1–1.4 CACNA1S; CACNA1C; CACNA1D; CACNA1F HVA α1S, C, D, F L
CaV2.1 CACNA1A HVA α1A P/Q
CaV2.2 CACNA1B HVA α1B N
CaV2.3 CACNA1E HVA α1E R
CaV3.1–3.3 CACNA1G; CACNA1H; CACNA1I LVA α1G, H, I. T
HVA: High Voltage activated; LVA: Low Voltage activated.
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The expression and properties of the pore forming α subunit are modified by two main auxiliary
or accessory subunits: α2δ and β, which regulate the channel’s biophysical properties, its trafficking,
and membrane expression. CaV1 and CaV2 channels can form heteromeric complexes co-assembling
with different α2δ subunits, which are encoded by CACNA2D1-4 genes, and β subunits, which are
encoded by CACNB1-4 genes. The stoichiometry of this assembly is of one β subunit and one α2δ
accessory subunit. An additional accessory subunit, γ, has been reported only in skeletal muscle [20].
1.2. CaV2.X Channels
The channels of the CaV2 family is formed by a pore-forming CaVα1 subunit plus the auxiliary
subunits CaVβ and CaVα2δ, with the CaVα1 subunit defining the channel subtype, as shown previously
(see Table 2). The CaV2.1 channels conduct currents classified as P-type and Q-type that are well
described in neurons, whereas the CaV2.2 and CaV2.3 channels underpin the N-type and R-type
currents, respectively, also characterized in neurons [23].
Cav2 channels are responsible for the Ca2+ influx required for the fast release of neurotransmitters
as well as for the release of hormones from secretory-type cells such as chromaffin cells [24].
CaV2 channels also regulate neuronal excitability via activation of the Ca2+ activated K+ channels that
in turn control repolarization and hyperpolarization [25]. Consistent with these functions, CaV2.1
null mice exhibit ataxia and die around 4 weeks after birth [26]. Mice deficient in CaV2.2 channels,
N-type, showed suppressed response to pain, which is consistent with the use of conotoxins as
analgesics [27], and with the expression of CaV2.2 channels in nerve terminals in association with
pain receptors. CaV2.2 channels are involved in neurotransmitter release of nociceptive pathways
from afferent terminals in the ventral and dorsal horn of the spinal cord and dorsal root ganglion
neurons [20,28]. CaV2.3 null mice also show reduced pain sensitivity [23].
1.3. General Properties of ω-Conotoxins
ω-conotoxins are small peptides ranging in size from 13 to 30 amino acids. They have net charges
between +5 and +7 [17], are mostly polar and are highly water soluble. They show three disulfide
bridges that are formed between conserved cysteine residues that are arranged in the following
organization, C-C-CC-C-C [29]; they form a common structural motif consisting of a cysteine knot,
which is also present in toxic and inhibitory polypeptides [30]. The ω-conotoxins family exhibit a
characteristic pattern signature described in the PROSITE database [31,32] (see Figure 1).
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Figure 1. ω-Conotoxins family pattern (PROSITE ID: PS60004). The pattern is described using the
following conventions: ‘x’ is used for a position where any amino acid is accepted; ambiguities are
indicated by listing the acceptable amino acids for a given position, between square parentheses ‘[ ]’,
i.e., [ALT] stands for Ala or Leu or Thr. Each element in the pattern is separated from its neighbor by a
‘-‘. Repetition of a pattern element can be indicated by following that element with a numerical value
or a numerical range in brackets. Examples: x(2) corresponds to x-x, x(1,5) corresponds to x or x-x or
x-x-x or x-x-x-x or x-x-x-x-x.
ost -conotoxins characterized to date are selective for N-type CaV channels. As indicated, the
main mechanism of action ofω-conotoxins’ is by blocking the channel pore [33], which is accomplished
by tight binding of the toxin to the channel pore [18]. The most studied and definedω-conotoxin is
GVIA isolated from Conus geographus [34]. Its specific activity against N-type Ca2+ channels—CaV2.2
channels- [35] was established in neuronal cell types [36]. Other ω-conotoxins from the venom of
different Conus species include CVID from the venom of Conus catus, CNVIIA from Conus consors and
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MVIIA, MVIIIV, and MVIID from Conus magus have been identified [37]. Additional ω-conotoxins
have been isolated from other Conus such as striatus [38], and magus [39].
2. Classification ofω-Conotoxins That Target CaV Channels
2.1. C. geographus—GVIA
GVIA. It consists of 27 amino acids with a backbone constrained by the formation of three
disulfide bonds (Cys1–Cys16, Cys9–Cys20, and Cys15–Cys26). The possible toxic effect of GVIA and
of the other members of the family such as GVIB, GVIC, GVIIA, and GVIIB was determined by
performing intracerebral injections in mice, which provoked involuntary movements (“shaking”) in
the animals [34] (Table 3). In vitro studies were first performed on nerve-muscle preparations of frogs
where GVIA irreversible blocked the voltage-activated Ca2+ channels of the presynaptic terminal
preventing acetylcholine exocytosis [13]. Together, these studies showed that GVIA selectively inhibits
CaV2.2 channels in an irreversible manner. The site of action of GVIA on CaV2.2 was found to be on
the large extracellular domain III between the S5–S6 trans-membrane regions [18]; mutagenesis studies
further showed that the reversibility of the block induced by GVIA and MVIIA was dramatically
enhanced by swapping a glycine residue at position 1326 for a proline. GVIA also binds the α1 subunit
of the Torpedo nAChR [13]. The 3D structures of GVIA resolved by NMR spectroscopy deposited in
the Protein Data Bank (PDB) are: 2CCO [40], 1TTL [41], and 1OMC [42].
2.2. C. magus—MVIIA and MVIIC
MVIIA. Also known as ziconotide is a 25 amino acid peptide that also blocks the pore of CaV2.2
channels (Table 3) and induced potent analgesia in rodents [43] and human patients with persistent
cancer pain [44]. In December 2004, the Food and Drug Administration (FDA) approved Prialt®
(commercial name for MVIIA) for the treatment of severe chronic pain using an intrathecal pump
system to deliver the drug into the cerebrospinal fluid. Consistent with this action, injection of
MVIIA into mammals caused important neuromuscular effects such as decrease of spontaneous and
coordinated locomotor activity and tremors [45]. It was shown that these effects and the pain relief
caused by delivery of MVIIA into the cerebrospinal fluid are mediated by inhibition of the release
of pro-nociceptive neurochemicals such as glutamate, calcitonin gene-related peptide (CGRP), and
substance P into the brain and spinal cord [46,47]. Site-mutagenesis studies revealed that the Met12
residue in loop 2 (Figure 2) is the responsible for the toxicity of MVIIA. Met12 interacts with the
hydrophobic pocket residues Ile300, Phe302, and Leu305, located between repeats II and III of CaV2.2
channels; this interaction disrupts the normal function of the channel [45]. Systematic mutations of the
residues in the loop 2 of MVIIA as well as of otherω-conotoxins may be used for future drug design to
develop modulators of CaV2.2 with lower side effects and higher effectiveness [45]. The 3D structures
of MVIIA resolved by NMR spectroscopy deposited in the PDB are: 1OMG [48], 1MVI [49], 1TTK [50],
1DW4 [51], and 1DW5 [51].
MVIIC. This toxin blocks CaV2.1 and CaV2.2 channels (Table 3). It possesses similar characteristics
to those described for MVIIA and its intracerebral injection in mice caused progressive decrease in
respiration rates with marked signs of gasping for breath. The peptide was lethal at low doses
(0.1–0.4 µg [52]). The 3D structures of MVIIC resolved by NMR spectroscopy deposited in the PDB are:
1OMN [53] and 1CNN [54].
2.3. C. striatus—SVIA and SVIB SO-3
SVIA and SVIB. The SVIA toxin contains 24 amino acids. Its administration into lower vertebrates
such as fish and frogs provokes paralysis [38], although it has relatively poor activity against
mammalian Ca2+ channels. While SVIA blocks only CaV2.2, SVIB blocks P/Q type and N-type channels
(Table 3). SVIB induces respiratory distress in mice when injected intracranially at concentrations of
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70 pmol/g mouse and it is lethal around 300 pmol/g mouse; SVIA administration does not kill mice
even at extremely high doses [38].
SO-3. Thisω-conotoxin shows analgesic activity similar to that of MVIIA when tested in models
of acute and chronic pain in rodents, however, it has fewer adverse effects than MVIIA [45,55]. The 3D
structure of SO-3 resolved by NMR spectroscopy deposited in the PDBe is: 1FYG [56].
2.4. C. catus—CVID
CVID. The sequence of its loop 4 is less conserved than other of ω-conotoxins. It displays the
highest selectivity for N-type over P/Q- type Ca2+ channels (radioligand binding assays) [57] and
because of this it has been tested in clinical trials as analgesic [58]. The 3D of CVID structure resolved
by NMR spectroscopy deposited in the PDB is: 1TT3 [50].
2.5. C. fulmen—FVIA
FVIA. It is reported to only be effective against CaV2.2 channels [59]. The 3D structure of FVIA
resolved by NMR spectroscopy deposited in the PDB is 2KM9 (to be published).
2.6. C. textile—TxVII and CNVIIA
TxVII. This conopeptide is very hydrophobic and has net negative charge of −3. The sequence of
TxVII is 58% identical to that of δ-conotoxin-TxVIA, which targets Na+ channels. This toxin blocks
the slowly inactivating, dihydropyridine- (DHP-) sensitive current [60]. The 3D of TxVII structure
resolved by NMR spectroscopy deposited in the PDB is: 1F3K [61].
CNVIIA. This toxin is closely related to the CnVIIH toxin (Table 3), which possesses an
unprocessed final glycine and therefore lacks amidation of its C-terminal end [62,63]. CNVIIA blocks
CaV2.2 channels but surprisingly it does not block the neuromuscular junction of amphibians.
Intracerebroventricular injection of CNVIIA in mice causes shaking movements and mild tremors,
depending on dosage, whereas when injected intramuscularly into fish it causes paralysis and death at
higher doses [62].
Table 3. ω-Conotoxins from Conus species and their targets.
Specie Conus ω-Conotoxin Alternative Names Target Organism IC50 Reference
C. geographus GVIA G6a, SNX-124,
CaV2.1 R. norvegicus 1.05 µM 1 [57]
CaV2.2 R. norvegicus 2.02 pM 1 [62]
GVIB ? [34]
GVIC ? [34]
GVIIA SNX-178 CaV2.2 R. norvegicus 22.9 nM 1 [64]
GVIIB ? [34]
C. magus MVIIA M7a, SNX-111, Ziconotide,
Prialt®
CaV2.1 R. norvegicus 156 nM 1 [62]
CaV2.2 H. sapiens 7.96 nM 2 [59]
MVIIB SNX-159 CaV2.2 R. norvegicus 101 pM 1 [65]
MVIIC M7c, SNX-230
CaV2.1 R. norvegicus 600 pM 1 [57]
CaV2.2 R. norvegicus 7.0 nM 1 [57]
MVIID SNX-238 ? [52]
C. striatus SVIA S6a, SNX-157 CaV2.2 R. norvegicus 1.46 µM 1 [65]
SVIB S6b, SNX-183
CaV2.1 [38]
CaV2.2 R. norvegicus 1.09 nM 1 [65]
SO-3 CaV2.2 160 nM 2 [45]
SO-4 ? [66]
SO-5 ? [66]
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Table 3. Cont.
Specie Conus ω-Conotoxin Alternative Names Target Organism IC50 Reference
C. catus CVIA C6a, catus-C1b
CaV2.1 R. norvegicus 850 nM 1 [57]
CaV2.2 R. norvegicus 560 pM 1 [57]
CVIB C6b CaV2.1CaV2.2
R. norvegicus
R. norvegicus
11 nM 1
7.7 nM 1
12 nM 2
[57]
[57]
[67]
CVIC C6c
CaV2.1 R. norvegicus 31 nM 1 [57]
CaV2.2 R. norvegicus 7.6 nM 1 [57]
CVID AM-336, AM336, leconotide
CaV2.1 R. norvegicus 55 µM 1 [57]
CaV2.2 R. norvegicus 70 pM 1 [57]
CVIE CaV2.2 R. norvegicus
2.6 nM 2
0.12 nM 2
[67]
CVIF C6f
CaV1.2 R. norvegicus >3 µM 2 [67]
CaV1.3 R. norvegicus >3 µM 2 [67]
CaV2.2 R. norvegicus 19.9 nM/ [67]
0.1 nM 2 [67]
CaV2.3 R. norvegicus >3 µM 2 [67]
C. fulmen FVIA CaV2.2 H. sapiens 11.5 nM 2 [59]
C. radiatus RVIA R6a CaV2.2 R. norvegicus 229 nM 1 [39]
C. textile TxVII L-type [60]
C. consors CnVIIA Cn7a, CnVIIH
CaV2.1 R. norvegicus 179 nM 1 [62]
CaV2.2 R. norvegicus 2.3–3.7 pM 1 [62]
CnVIIB CnVIIG ? [63]
CnVIIC CnVIIE ? [63]
C. pennaceus PnVIA Pn6a ? Lymnaeastagnalis ~5 µM
2 [68]
PnVIB Pn6b ? Lymnaeastagnalis ~5 µM
2 [68]
C. tulipa TVIA SNX-185 CaV2.2 R. norvegicus 228 pM 1 [65]
1 Binding/competition assay; 2 Electrophysiological measurements.
3. Structural Characteristics ofω-Conotoxins and Blockade Site on the CaV Channels
ω-conotoxins share several structural characteristics that allow them to block multiple CaVs on
diverse cell types. Here we explore in detail four well known ω-conotoxins, CVID, SVIB, GVIA,
and MVIIA, whose 3D structures have been resolved by NMR except for CVID (PDB IDs 1MVJ [49],
2CCO [40], and 1MVI [49], respectively); their multiple sequence alignments as well as their 3D
structures are shown in Figure 2. As previously noted, they share four loops and three disulfide bonds
(Figure 2A,C), giving them the same structural pattern (Figure 2B). These similarities are evident
between CVID and SVIB (RMSDbackbone = 0.109 Å), although they are more subtle between CVID and
GVIA (RMSDbackbone = 1.635 Å) (Figure 2D). The main structural differences between loops 2 and 3
(structural difference 1) and 4 (structural difference 2), where ω-conotoxins residues are not highly
conserved, are highlighted with gray boxes (Figure 2B). Despite the structural similarities, there are
differences in the selectivity of targets between these toxins. To understand the selectivity of these
toxins at the structural basis, using NMR spectroscopy, researchers have determined the secondary
and tertiary structures [50]. Adams et al. found a correlation between the solvent accessible surface
area and the selectivity ofω-conotoxins, where the most exposed residue, R10 in MVIIA, play a crucial
role in binding to CaVs [50]. The residue(s) on CaV channels that interacts withω-conotoxins is not yet
elucidated, although the extracellular linker region between the P-region and S5 in domain III, the
pore of CaV2.2, is reported to be the area where the toxins bind channels [17,33]. In this region, G1326
appears to be the essential residue, as its mutation modifies the access of GVIA and MVIIA to the
active site [69].
The structure-activity relationship (SAR) studies conducted in conotoxins identified key residues
involved in the interaction with protein targets as well as identification of specific amino acids involved
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in their structural arrangement. These studies have been used to design small bioactive mimetics to
selectively block CaV2.2 over CaV2.1 channels [70,71]. Bioactive mimetics have become promising
candidates in the search for novel drugs for the treatment of chronic pain [21]. For example, based
on the 3D structure of MVIIA [48] and identification of key residues such as K2, R10, L11, Y13, and
R21 involved in the binding of MVIIA [72]. The data collected gave fundamental information for
the design of the first bioactive mimetic of MVIIA in 1998, including the draft of small structures to
mimic the residues R10, L11, and Y13 [73]. Although this bioactive mimetic showed poor inhibition
against CaV2.2 (19% at 10 µM), a second generation of mimetics was produced and two of these
compounds showed promising activities against CaV2.2 (IC50 = 3.3 and 2.7 µM) [74]. Since then, others
ω-conotoxins mimetics have been reported using SAR information [70,75,76].Mar. Drugs 2017, 15, 313 8 of 14 
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as 1 and 2. (C) ω-conotoxins in ribbon representation with disulfide bonds in stick representation.
(D) RMSD (Å) matrix fr mω-c notoxins backbone atoms structural alignment.
4. Therapeutic Uses of Conotoxins
The therapeutic and pharmacological potential of the conotoxins is well-known [1,47,77].
Nevertheless, their intrinsic physic-chemical and therapeutic characteristics such as molecular weight
and low bioavailability due to their susceptibility to peptidase degradation has prevented the
widespread use of onotoxins in th clinic. Importantly, and despite these limitations, their ability to
selectively bind closely related molecular targets is an important strength of these marine conopeptides.
Another advantage of Conotoxins is the diversity of targets, as they can act upon ion channels
such as KV, NaV, and CaV channels, as well as on several G-protein coupled receptors including
neurotensin, α-adren rgic, nd vasopressin rec pt rs and also on ligand-gated receptors such as
AChRs, 5HT3Rs, and NMDARs [77]. These properties make them excellent candidates to develop new
bio-compounds and derivatives against pathologies such as pain, stroke, and convulsive disorders.
Especially interesting is their specific affinity for N-type, CaV2.2, CaV channels, which is a useful
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pharmacological characteristic for the validation of molecular targets, for example, in neuropathic pain.
CaVs channel-mediated cellular events can be modulated for therapeutic purposes by direct block of
CaV2.2, i.e., small peptides as conotoxins; by activation of GPCRs, or by direct interference with the
channel trafficking [23].
In nature the proteins targeted by the cone snails on the preys are closely related to the proteins
targeted in humans; however small structural and physiological differences can modify the efficacy,
selectivity, and potency of conotoxins. Moreover, the target protein in cone snail’s preys may serve
functions that are distinct to those in humans. Further, in humans and mammals the target proteins
may be found in protected physiological spaces such as the Central Nervous System [77].
The recent significant progress in the identification of novel pharmacological targets for analgesic
drugs designed using natural products has promoted the therapeutic use of conotoxins in pain
relief. The main analgesic conopeptide is the ω-conotoxin MVIIA (Prialt®), which was approved
for the management of severe chronic pain [43,47]. Prialt® is being manufactured and labeled by
Jazz Pharmaceuticals and Eisai Limited in the US and the European Union, respectively. Prialt®
blocks selectively N-type CaV channels through the inhibition of the presynaptic neurotransmitter
release [13,78]. Prialt® attenuates nociception in several animal models such as models of persistent
pain [79], chronic inflammatory pain [80], neuropathic pain [81], and postoperative pain [43]. Prialt®
showed high effectiveness in morphine tolerant murine models [82], and prolonged Prialt® intrathecal
infusion does not produce tolerance to its analgesic effects [79,82]. Anotherω-conotoxin with analgesic
activity is CVID (AM336), a conopeptide selective for N-type Ca channels [83], although it might have
greater side effects than MVIIA [83]. Other conotoxins used in analgesia are Contulakin-G (CGX-1160),
MrIA (Xen-2174), Conantokin-G (CGX-1007), Vc1.1 (ACV-1), and MrVIB (CGX-1002) [77].
The pharmacological and therapeutically pre-clinical efficacy of MVIIA and CVID, along with
the FDA approval of Prialt®, have established ω-conotoxins (and conotoxins in general) as viable
platforms for the design of new and specific drugs to alleviate pain by aiming N-type CaV channels.
5. Conclusions
Neuronal CaV channels have potential as targets for treatments of pain and the selectivity of
conotoxins for these channels render conopeptides valuable therapeutic tools. ω-conotoxins display
an inhibitory cysteine knot which is also present in other toxic peptides. This motif, along with other
common structural characteristics, is the basis of their potent and selective blocking activity on the
pore of CaV channels. A ω-conotoxin, MVIIA, has been approved by the FDA for therapeutic use
under the commercial name of Prialt®. Going forward, however, more widespread applications of
conotoxins will require improvements to enhance their transport across the blood-brain barrier as well
as modification to increase their chemical stability.
The association between the structure of ω-conotoxins and their activity against CaV channels
remains undetermined and such knowledge will be fundamental to improve their use as therapeutic
agents. Techniques such as circular dichroism and NMR spectroscopy have been helpful in the
development of SAR studies, which have aided in the design of MVIIA [84], and GVIA [85] analogues.
Additionally, the combination of electrophysiology, computational biophysics approaches, and
SAR studies has provided new insights into the molecular binding mechanism of ω-conotoxins
to their targets. This knowledge now places the drug design processes targeting chronic pain in
a robust position to develop novel therapeutic agents. The design of small mimetics requires the
identification of the correct scaffolds as well as of key residues to mimic. Towards this end, non-peptide
mimetics containing the scaffolds of dendritic, 8-hydroxy-2-(1H)-quinolinone and the 5-hydroxymethyl
resorcinol and the residues Leu, Arg, and Tyr, which matched the pharmacophore found in the
conotoxin, were developed as MVIIA mimetics and show promissory biological activities against
CaV2.2. Conotoxins remain an attractive option for the development of new therapeutic strategies using
bioactive mimetics against chronic pain. Nevertheless, additional work involving both experimental
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and theoretical approaches are needed to unravel at the structural level the mechanisms modulating
the protein targets of these peptides.
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